Skip to main content

Table 3 The initially applied empirical antimicrobial therapies

From: Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study

  Total (n = 61) ITV group (n = 38) ITV + ITC group (n = 23) P
Before infection (n, %)     0.684
M/I + vancomycin 23, 37.70% 15, 39.47% 8, 34.78%  
M/I + linezolid 9, 14.75% 7, 18.42% 2, 8.70%  
M/I + cefperazone-sulbactam 2, 3.28% 2, 5.26% 0, 0.00%  
M/I 11, 18.03% 7, 18.42% 4, 17.39%  
Tigecycline + cefperazone-sulbactam 10, 16.39% 6, 15.78% 4, 17.39%  
Tigecycline 2, 3.28% 1, 2.63% 1, 4.34%  
Ceftriaxone 4, 6.56% 4, 10.53% 0, 0.00%  
Cefperazone-sulbactam + vancomycin 1, 1.64% 1, 2.63% 0, 0.00%  
Cefperazone-sulbactam 3, 4.92% 3, 7.89% 3, 13.04%  
Piperacillin-tazobactam 6, 9.84% 6, 15.79% 7, 30.43%  
After infection (n, %)     0.723
M/I + amikacin 3, 4.92% 3, 7.89% 0, 0.00%  
M/I + tigecycline 12, 19.67% 8, 21.05% 4, 17.39%  
M/I + cefperazone-sulbactam 7, 11.48% 4, 10.52% 3, 13.04%  
M/I 11, 18.03% 8, 21.05% 3, 13.04%  
Tigecycline+cefperazone-sulbactam 19, 31.15% 10, 6.32% 9, 39.13%  
Cefperazone-sulbactam 8, 13.11% 4, 10.53% 4, 17.39%  
Cefperazone-sulbactam + amikacin 1, 1.64% 1, 2.63% 0, 0.00%  
  1. ITV intravenous, ITV + ITC intrathecal/intracerebral, /I meropenem/imipenem